Repligen Co. (NASDAQ:RGEN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Repligen Co. (NASDAQ:RGEN) have been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $185.20.

A number of brokerages recently commented on RGEN. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Finally, Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company.

Repligen Trading Up 3.5 %

Shares of NASDAQ RGEN opened at $162.85 on Friday. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The business has a fifty day simple moving average of $147.96 and a two-hundred day simple moving average of $144.21. The firm has a market cap of $9.12 billion, a PE ratio of -440.12, a price-to-earnings-growth ratio of 4.14 and a beta of 0.97.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the prior year, the firm earned $0.23 earnings per share. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. Analysts expect that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

Several institutional investors have recently bought and sold shares of the company. UMB Bank n.a. increased its position in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. boosted its stake in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares during the last quarter. Resources Management Corp CT ADV acquired a new stake in Repligen during the 3rd quarter worth $37,000. Quarry LP grew its holdings in shares of Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in shares of Repligen in the third quarter valued at about $45,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.